MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status.
about
Metabolomic profiling of hormone-dependent cancers: a bird's eye viewMagnetic resonance spectroscopy detectable metabolomic fingerprint of response to antineoplastic treatmentIdentification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancerSilencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by (31) P MRS.Biochemical characterization of breast tumors by in vivo and in vitro magnetic resonance spectroscopy (MRS)Serum Metabolomic Profiles for Breast Cancer Diagnosis, Grading and Staging by Gas Chromatography-Mass Spectrometry.Quantitative measurement of organic acids in tissues from gastric cancer patients indicates increased glucose metabolism in gastric cancer.BI-RADS 3-5 microcalcifications: prediction of lymph node metastasis of breast cancerBreast Tissue Metabolism by Magnetic Resonance Spectroscopy.Predicting protein phenotypes based on protein-protein interaction network.In vivo MRS of locally advanced breast cancer: characteristics related to negative or positive choline detection and early monitoring of treatment response.An HR-MAS MR metabolomics study on breast tissues obtained with core needle biopsyPrognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy.Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance.Early detection of recurrent breast cancer using metabolite profiling.HR-MAS MR spectroscopy of breast cancer tissue obtained with core needle biopsy: correlation with prognostic factors.Feasibility of MR metabolomics for immediate analysis of resection margins during breast cancer surgeryAnalysis of cancer tissues by means of spectroscopic methodsMetabolic characterization of triple negative breast cancer.Magnetic resonance metabolic profiling of breast cancer tissue obtained with core needle biopsy for predicting pathologic response to neoadjuvant chemotherapyFollicular adenomas exhibit a unique metabolic profile. ¹H NMR studies of thyroid lesionsLeveraging metabolomics to assess the next generation of temozolomide-based therapeutic approaches for glioblastomasMagic angle spinning NMR-based metabolic profiling of head and neck squamous cell carcinoma tissuesApplication of metabolomics in thyroid cancer research.Serum metabolomics analysis reveals changes in signaling lipids in breast cancer patients.Metabolic tumor imaging using magnetic resonance spectroscopy.(1)H nuclear magnetic resonance-based extracellular metabolomic analysis of multidrug resistant Tca8113 oral squamous carcinoma cells.Metabolomics of Breast Cancer Using High-Resolution Magic Angle Spinning Magnetic Resonance Spectroscopy: Correlations with 18F-FDG Positron Emission Tomography-Computed Tomography, Dynamic Contrast-Enhanced and Diffusion-Weighted Imaging MRIMetabolite profiling in retinoblastoma identifies novel clinicopathological subgroups.Metabolomic signature of brain cancer.Principal component analysis for the comparison of metabolic profiles from human rectal cancer biopsies and colorectal xenografts using high-resolution magic angle spinning 1H magnetic resonance spectroscopy.HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease.Clinical applications of metabolomics in oncology: a review.Metabolomics-based methods for early disease diagnosticsPrediction of gene phenotypes based on GO and KEGG pathway enrichment scores.Genomic and proteomic biomarkers for cancer: a multitude of opportunities.Use of nuclear magnetic resonance-based metabolomics in detecting drug resistance in cancerTriple-negative breast cancer: present challenges and new perspectives.Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy.Metabolomics and detection of colorectal cancer in humans: a systematic review.
P2860
Q28084834-897D7CCA-2971-4140-A43D-F925F960B5A1Q28477468-3BDF4E55-089E-469D-9DA8-1945090FC78DQ28478197-34B040BB-1B1B-4AAE-A25F-0FCA9591DCB5Q30808489-B3BC911F-14C2-434F-821D-6CE3AA99F1D4Q33552272-DC78D262-0C9B-4E33-811B-784B5B0695E6Q33687106-C929F2F7-4F18-4268-8060-D9B32456E431Q33727137-FC07FCDE-DE89-4761-8629-83279F8EDC20Q33728272-9165DA22-7D5E-4095-990B-7A0ACDB3343AQ33844954-D64C5CB9-0DED-4203-B198-0710EB7D7F86Q33851525-51B32F4D-11B6-4DB0-93CE-209DC28FCD64Q34016780-C151FB83-BB37-4AF3-986C-B97EA6982AFDQ34058288-8A8DD3C8-04CA-4A29-8DF6-7C33AD8CE9FCQ34140986-C0077A14-6A8F-4CE8-96BD-485CC2BAC01FQ34346725-D10F57F6-3271-407F-85BB-1665E72A1287Q34369288-255CEAB8-BCF2-4BD8-B301-CF4A2E0F45BCQ34525558-139611E6-B1BA-4DE3-BD60-7A5207EF557FQ34684585-079F2B15-EF13-4BD3-9836-8FFE4D6421A0Q34780175-DEA3D075-4B25-4348-9E00-011D11F47A12Q34967995-8339CA1E-A79E-4183-A3DF-DAB7113919C1Q35075617-A715A3BE-846A-4B59-96FB-D42E6233D7B2Q35078436-634F554D-0DE0-46C9-B7DD-0B36FAD44297Q35171890-2346E5ED-C200-4504-AA99-52C125A181BFQ35529046-B47717ED-D6BD-4FE1-B385-7D32201E588DQ35564078-9F0E84C3-E18F-48CE-91D5-DF72987637C2Q35693105-29E2BCF9-4E1A-4F3E-B22D-4E513BFED05DQ35746099-D0F35CBE-18E0-42CF-BCEF-2D2128A0CB2FQ35758072-AE9A22C3-2429-4F67-A752-94B4E731C848Q36086056-BA6DC1A5-CC30-4E1D-B77A-A0526CF04AB4Q36287393-72BA82E9-0750-4E03-BF0C-AC04ACD0C87AQ36406413-B18EA8C2-727F-4BFC-BF48-8B0533192F4AQ36649292-1AA95A8A-3554-4936-A1A2-4557E3192911Q37044305-C4B952ED-084E-4EB5-9706-4E57C888828CQ37177549-19092390-F554-40A5-B239-F1D7E79FE646Q37266489-380214C5-2361-42F4-9E7B-B958B92B7B9AQ37338200-530560A9-E6A1-4D26-93E7-BDAAA6691BC6Q37363928-5F13395E-83FB-4E7F-99B6-487B9F8EEB0FQ37374479-9FCA8AF6-C2F8-4FBB-AA02-24171234173BQ37764168-790E4C6B-944F-4FEF-8EAE-4CE5F5E58243Q37780690-C3ACE1F0-380C-4EE4-9BB9-605E3775A105Q37797462-93D78FC8-7EB7-4A5C-9736-1BCE104B0A83
P2860
MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
MR-determined metabolic phenot ...... ad, grade, and hormone status.
@en
type
label
MR-determined metabolic phenot ...... ad, grade, and hormone status.
@en
prefLabel
MR-determined metabolic phenot ...... ad, grade, and hormone status.
@en
P2093
P2860
P50
P1476
MR-determined metabolic phenot ...... ad, grade, and hormone status.
@en
P2093
David E Axelson
Hans E Fjösne
Line R Jensen
P2860
P2888
P304
P356
10.1007/S10549-006-9400-Z
P407
P577
2006-10-24T00:00:00Z
P6179
1029128283